Roche Holding AG (RHHVF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 03:48PM EDT
| Previous Close | 261.27 |
| Open | 261.27 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 260.00 - 263.86 |
| 52 Week Range | 233.12 - 323.78 |
| Volume | |
| Avg. Volume | 9,930 |
| Market Cap | 211.085B |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | 16.45 |
| EPS (TTM) | 15.90 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 10.86 (4.15%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | N/A |
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Barrons.comDow Hitting 40,000 Is Good but Look Here for Where Markets Are Headed, and 5 Other Things to Know Today.
Reddit content is coming to OpenAI’s chatbot, Roche’s weight-loss drug impresses analysts in early-stage trials, and other news to start your day.
Barrons.comRoche’s New Weight-Loss Data Shows Lilly Isn’t Unbeatable in Obesity
The results, from a small trial of a drug called CT-388, hint that Roche could be a serious player in the weight-loss market in coming years.
© 2024 Yahoo. All rights reserved.